A preprint study by the nference research team has identified 652 patients whose clinical notes confirmed use of purported retatrutide, an investigational drug from Eli Lilly that the Food and Drug Administration has not approved for any use. The study, reported by the Los Angeles Times, provides what appears to be the first large-scale clinical documentation of gray-market retatrutide sourcing patterns.
Of 531 patients with a documented source, 71.2% reported obtaining the drug outside a clinical trial, and 57.4% of those individuals sourced it through online or telehealth vendors. The findings illuminate the scale of an unapproved market for a drug still in the experimental stage.
What happened
The preprint study analyzed clinical notes to identify patients who used purported retatrutide, a triple-hormone-receptor agonist under development by Eli Lilly. The FDA has not approved retatrutide for any indication.
Among the 652 patients identified, 531 had documentation of where they obtained the product. Of those, 378 patients (71.2%) reported sourcing it outside a clinical trial. Within that group, 217 patients (57.4%) said they obtained it through online or telehealth vendors.
The study recorded patient-reported sourcing data, offering a clinical window into how an unapproved, investigational drug reaches consumers outside regulated channels.
Important caveat: The study is a preprint and has not completed peer review. Its findings should be considered preliminary.
Why it matters
This study represents the first systematic clinical documentation of gray-market retatrutide use at scale. The sourcing data could inform FDA enforcement priorities and regulatory policy decisions surrounding unapproved investigational drugs.
The finding that the majority of patients obtained the drug through online vendors rather than clinical channels underscores both the reach of the unapproved market and the enforcement challenge facing regulators. Affected groups include peptide consumers, telehealth platforms, compounding pharmacies, Eli Lilly, FDA regulators, and state pharmacy boards.
Retatrutide remains an investigational compound. The study did not establish the safety, efficacy, or quality of the products patients obtained outside clinical trials, and the sourcing data reflects patient-reported information documented in clinical notes.
What to watch next
- Whether the preprint undergoes peer review and publication in a medical journal
- Potential FDA or state regulatory responses to the documented gray-market sourcing patterns
- Whether Eli Lilly takes additional enforcement or legal action regarding unauthorized retatrutide distribution
- Further research on patient outcomes associated with gray-market retatrutide use
Sources
Industry information only. Not medical or legal advice.
